The invention relates to a pharmaceutical composition for contraception c ontaining, in a daily dose, 2.0 mg or 1.5 mg of 17.alpha.-cyanomethyl-17-ss-h ydroxyestra-4,9-diene-3on (dienogest) and 0.015 mg of 17.alpha.-ethinylestra diol (ethinylestradiol) and (6S)-5-methyltetrahydrofolate, preferably as cal cium salt of the (6S)-5-methyltetrahydrofolic acid (metafolin) together with one or more pharmaceutically acceptable auxiliary agents/carriers. The inve ntive pharmaceutical composition is an oral contraceptive as well as an agen t for reducing the risk of congenital malformations. The invention also rela tes to a kit comprising 21 daily dose units of the pharmaceutical compositio n and 7 daily dose units containing only (6S)-5-methyltetrahydrofolate, pref erably also metafolin.
